Infographics - Chronic Liver Diseases Therapeutics Market

The liver is the largest solid internal organ of the body and performs various roles that include the creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases, which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper liver functioning are obesity, excessive alcohol consumption, and genetic disorder. The treatment options available to treat liver diseases include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.

Market Dynamics

The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in December 2022, Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver disease, announced positive topline results from its 24-week (12-week extension) trial of Pemvidutide for non-alcoholic fatty liver disease, showing the potential to dramatically lower liver fat content and liver inflammation. Moreover, in January 2022, Madrigal Pharmaceuticals, Inc. l is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, announced positive topline clinical data from the placebo-controlled, double-blind version of its phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety study of Resmetirom.

Key features of the study:

This report provides an in-depth analysis of the global chronic liver diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Chronic Liver Diseases Therapeutics market.

Detailed Segmentation:

Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:
- Antiviral drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
Global Chronic Liver Diseases Therapeutics Market, By Disease Type:
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Cancer
- Genetic Disorders
- Others
Global Chronic Liver Diseases Therapeutics Market, By Distribution type:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chronic Liver Diseases Therapeutics, By Region:
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- Astellas Pharma Inc
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

Table of Contents

Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Treatment Type
  - Market Snippet, By Disease Type
  - Market Snippet, By Distribution type
  - Market Snippet, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
Global Chronic Liver Diseases Therapeutics Market– COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
Global Chronic Liver Diseases Therapeutics Market, By Treatment Type, 2018–2030 (US$ Bn)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2019–2030
  - Segment Trends
- Antiviral Drugs
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Immunosuppressants
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Vaccines
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Immunoglobulins
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Corticosteroids
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Targeted Therapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Chemotherapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
Global Chronic Liver Diseases Therapeutics Market, By Disease Type, 2018–2030 (US$ Bn)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2019–2030
  - Segment Trends
- Hepatitis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Autoimmune Diseases
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Non-alcoholic Fatty Liver Disease (NAFLD)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Genetic Disorders
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
Global Chronic Liver Diseases Therapeutics Market, By Distribution type, 2018–2030 (US$ Bn)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2019–2030
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
Global Chronic Liver Diseases Therapeutics Market, By Regions, 2018–2030 (US$ Bn)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2019–2030
  - Segment Trends
- North America
  - Introduction
  - Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
    - U.S.
    - Canada
- Europe
  - Introduction
  - Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Latin America
  - Introduction
  - Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Middle East
  - Introduction
  - Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Company Profiles
  - Astellas Pharma Inc
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Bristol-Myers Squibb
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Gilead Sciences
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - GlaxoSmithKline Plc
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - F. Hoffmann-La Roche Ltd.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Merck & Co. Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Novartis AG
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Sanofi S.A
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Pfizer Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Takeda Pharmaceutical
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Valeant Pharmaceuticals
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Watson Pharmaceuticals, Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Theratechnologies Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Alnylam Pharmaceuticals, Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Protagonist Therapeutics, Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Dicerna Pharmaceuticals, Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Endo International
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Provectus Biopharmaceuticals Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - MAX BioPharma, Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
Section
- References
- Research Methodology
- About us and Sales Contact

*Browse 30 market data tables and 24 figures on “Chronic Liver Diseases Therapeutics Market– Global forecast to 2030

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount